Prevention and Management of Cerebral Small Vessel Disease

Lacunar infarcts/lacunes, white matter hyperintensities (WMH), and cerebral microbleeds (CMBs) are considered various manifestations of cerebral small vessel disease (SVD). Since the exact mechanisms of these manifestations differ, their associated risk factors differ. High blood pressure is the mos...

Full description

Bibliographic Details
Main Authors: Vincent Mok, Jong S. Kim
Format: Article
Language:English
Published: Korean Stroke Society 2015-05-01
Series:Journal of Stroke
Subjects:
Online Access:http://www.j-stroke.org/upload/pdf/jos-17-111.pdf
id doaj-0d5513928484488788cb881a7c7fbcac
record_format Article
spelling doaj-0d5513928484488788cb881a7c7fbcac2020-11-25T03:38:44ZengKorean Stroke SocietyJournal of Stroke2287-63912287-64052015-05-0117211112210.5853/jos.2015.17.2.11173Prevention and Management of Cerebral Small Vessel DiseaseVincent MokJong S. KimLacunar infarcts/lacunes, white matter hyperintensities (WMH), and cerebral microbleeds (CMBs) are considered various manifestations of cerebral small vessel disease (SVD). Since the exact mechanisms of these manifestations differ, their associated risk factors differ. High blood pressure is the most consistent risk factor for all of these manifestations. However, a "J curve" phenomenon in terms of blood pressure probably exists for WMH. The association between cholesterol levels and lacunar infarcts/lacunes or WMH was less consistent and sometimes conflicting; a low cholesterol level probably increases the risk of CMBs. Homocysteinemia appears to be associated with WMH. It is noteworthy that the risk factors profile may also differ between different lacunar patterns and CMBs located at different parts of the brain. Thrombolysis, antihypertensives, and statins are used to treat patients with symptomatic lacunar infarction, just as in those with other stroke subtypes. However, it should be remembered that bleeding risks increase in patients with extensive WMH and CMBs after thrombolysis therapy. According to the Secondary Prevention of Small Subcortical Strokes trial results, a blood pressure reduction to <130 mmHg is recommended in patients with symptomatic lacunar infarction. However, an excessive blood pressure decrease may induce cognitive decline in older patients with extensive WMH. Dual antiplatelet therapy (aspirin plus clopidogrel) should be avoided because of the excessive risk of intracerebral hemorrhage. Although no particular antiplatelet is recommended, drugs such as cilostazol or triflusal may have advantages for patients with SVD since they are associated with less frequent bleeding complications than aspirin.http://www.j-stroke.org/upload/pdf/jos-17-111.pdfpreventiontreatmentsmall vessel disease
collection DOAJ
language English
format Article
sources DOAJ
author Vincent Mok
Jong S. Kim
spellingShingle Vincent Mok
Jong S. Kim
Prevention and Management of Cerebral Small Vessel Disease
Journal of Stroke
prevention
treatment
small vessel disease
author_facet Vincent Mok
Jong S. Kim
author_sort Vincent Mok
title Prevention and Management of Cerebral Small Vessel Disease
title_short Prevention and Management of Cerebral Small Vessel Disease
title_full Prevention and Management of Cerebral Small Vessel Disease
title_fullStr Prevention and Management of Cerebral Small Vessel Disease
title_full_unstemmed Prevention and Management of Cerebral Small Vessel Disease
title_sort prevention and management of cerebral small vessel disease
publisher Korean Stroke Society
series Journal of Stroke
issn 2287-6391
2287-6405
publishDate 2015-05-01
description Lacunar infarcts/lacunes, white matter hyperintensities (WMH), and cerebral microbleeds (CMBs) are considered various manifestations of cerebral small vessel disease (SVD). Since the exact mechanisms of these manifestations differ, their associated risk factors differ. High blood pressure is the most consistent risk factor for all of these manifestations. However, a "J curve" phenomenon in terms of blood pressure probably exists for WMH. The association between cholesterol levels and lacunar infarcts/lacunes or WMH was less consistent and sometimes conflicting; a low cholesterol level probably increases the risk of CMBs. Homocysteinemia appears to be associated with WMH. It is noteworthy that the risk factors profile may also differ between different lacunar patterns and CMBs located at different parts of the brain. Thrombolysis, antihypertensives, and statins are used to treat patients with symptomatic lacunar infarction, just as in those with other stroke subtypes. However, it should be remembered that bleeding risks increase in patients with extensive WMH and CMBs after thrombolysis therapy. According to the Secondary Prevention of Small Subcortical Strokes trial results, a blood pressure reduction to <130 mmHg is recommended in patients with symptomatic lacunar infarction. However, an excessive blood pressure decrease may induce cognitive decline in older patients with extensive WMH. Dual antiplatelet therapy (aspirin plus clopidogrel) should be avoided because of the excessive risk of intracerebral hemorrhage. Although no particular antiplatelet is recommended, drugs such as cilostazol or triflusal may have advantages for patients with SVD since they are associated with less frequent bleeding complications than aspirin.
topic prevention
treatment
small vessel disease
url http://www.j-stroke.org/upload/pdf/jos-17-111.pdf
work_keys_str_mv AT vincentmok preventionandmanagementofcerebralsmallvesseldisease
AT jongskim preventionandmanagementofcerebralsmallvesseldisease
_version_ 1724540807668563968